Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Kymera Therapeutics Inc(KYMR)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for KYMR
09/25/2026: KYMR (4-star) is currently NOT-A-BUY. Pass it for now.
Kymera Therapeutics is a clinical-stage biotechnology company focused on the innovative field of targeted protein degradation to address various diseases. The company is known for its proprietary Pegasus platform and strategic partnerships, notably with Sanofi, which help validate its scientific approach. Its main opportunity lies in successfully advancing its lead pipeline assets like KT-474 through clinical trials to potential market approval. Risks include the inherent uncertainty of drug development, substantial cash burn, and intense competition from larger, well-capitalized biotech firms. This stock is best suited for growth-oriented investors with a high risk tolerance who are prepared to monitor clinical data milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers high growth potential as a pioneer in the emerging targeted protein degradation market. |
| Momentum investor | Mixed fit | Momentum is conditional on positive clinical data readouts and supportive market sentiment toward biotech. |
| Value investor | Weak fit | The company has no current earnings or commercial products, making traditional valuation metrics inapplicable. |
| Dividend investor | Weak fit | As a clinical-stage biotech, Kymera does not pay dividends. |
| Low-risk investor | Weak fit | The inherent risks of drug development and high price volatility are not suitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks are highly sensitive to news cycles and clinical data readouts. |
| Valuation risk | High | Valuations are based on long-term future projections rather than current cash flow. |
| Competition risk (targeted protein degradation) | Medium / high | Several well-capitalized competitors are also pursuing similar therapeutic modalities. |
| Business quality | Medium | While the platform is robust, the company is still unproven in bringing a drug to commercial market. |
| Dividend income | Low / none | The company is in an early growth phase and does not generate income for shareholders. |
| Execution risk | High | Success is heavily dependent on achieving complex R&D and clinical milestones. |
Price Behavior
Hockey-Stick Growth
The stock demonstrates a Hockey-Stick Growth price path pattern.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 98.77% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.31B USD | Price to earnings Ratio - | 1Y Target Price 138.64 |
Price to earnings Ratio - | 1Y Target Price 138.64 | ||
Volume (30-day avg) 701.6K shares | Beta 1.97 | 52 Weeks Range 54.09 - 130.05 | Updated Date 09/26/2026 |
52 Weeks Range 54.09 - 130.05 | Updated Date 09/26/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.25 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Collaboration and Licensing | Upfront payments, milestone payments, and future royalties from strategic partnerships like Sanofi. | Kymera is currently funded by the development deals it signs with larger pharmaceutical partners. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8.98B | Price to Sales(TTM) 87.7 |
Enterprise Value 8.98B | Price to Sales(TTM) 87.7 | ||
Enterprise Value to Revenue 85.56 | Enterprise Value to EBITDA -9.49 | Shares Outstanding 83.15M | Shares Floating 66.01M |
Shares Outstanding 83.15M | Shares Floating 66.01M | ||
Percent Insiders 2.12 | Percent Institutions 119.27 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Kymera Therapeutics Inc
Exchange NASDAQ | Headquarters Watertown, MA, United States | ||
IPO Launch date 2020-08-21 | Co-Founder, President, CEO & Director Dr. Nello Mainolfi M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 273 | Website https://www.kymeratx.com |
Full time employees 273 | Website https://www.kymeratx.com | ||
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.